International Center for Biomedicine (ICC) and Laboratory of Cellular and Molecular Neurosciences, University of Chile. Las Encinas 3370, Ñuñoa, Santiago, Chile.
Curr Alzheimer Res. 2011 Sep;8(6):652-8. doi: 10.2174/156720511796717203.
A major limitation in finding therapeutic solutions for Alzheimer's disease (AD) has been the lack of a reliable method for early diagnosis of this devastating disease. Besides the development of biomarkers in biological fluids of patients, the search for a pathology-specific neuroimaging tools is critical at the present stage in which almost 30 million people suffer this disease worldwide. Several interesting approaches have been developed, however their clinical impact has been low. One of the difficulties has been to find the proper molecular tracers to specifically tag pathognomonic lesions in AD brain, including not only amyloid aggregates but also filaments of the modified microtubule-associated protein tau. In this review, we analyze the evidence towards developing pathology-specific diagnostic tools for AD. We analyze the current evidence and clinical implications of new imaging technologies for AD, and how tau hypothesis and the amyloid cascade hypothesis will impact on these scientific efforts in the near future.
在寻找阿尔茨海默病（AD）治疗方法方面存在一个主要限制，即缺乏可靠的早期诊断方法。除了在患者的生物体液中开发生物标志物外，在现阶段寻找特定于病理学的神经影像学工具至关重要，因为目前全世界有近 3000 万人患有这种疾病。已经开发了几种有趣的方法，但是它们的临床影响却很低。困难之一是找到合适的分子示踪剂来特异性标记 AD 大脑中的病理病变，包括不仅淀粉样蛋白聚集物，还有修饰的微管相关蛋白 tau 的纤维。在这篇综述中，我们分析了开发 AD 病理学特异性诊断工具的证据。我们分析了 AD 新成像技术的当前证据和临床意义，以及 tau 假说和淀粉样蛋白级联假说将如何在不久的将来影响这些科学努力。
